S1417CD Financial Impact Assessment Tool in Patients With Metastatic Colorectal Cancer
Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVB Colon Cancer, Stage IVB Rectal Cancer
ClinicalTrials.gov recordTREATMENT READING
Source sections for this topic, with the original link and date. Patient and professional reading are labelled separately.
Not medical advice · Not a complete treatment or trial directory
Made by Triangle.
Selected text from the National Cancer Institute, with the original link and date. Made by Triangle. This page is not an NCI PDQ summary. Source topics may be broader than an individual diagnosis.
Source: Financial Toxicity and Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 29, 2024. Captured 2026-09-09.
Patients with advanced-stage cancers, cancers requiring chemotherapy or radiation therapy, and underlying comorbidities have a higher risk of financial hardship after diagnosis than those without these characteristics.[1-4] In a study of 1,556 cancer survivors identified from the 2010 National Health Interview Survey (NHIS) who responded to a single survey item assessing financial burden, survivors were more likely to report high financial burden if they received chemotherapy (47.2% vs. 30.8%; P < .001), received radiation therapy (44.7% vs. 31.4%; P < .001), and had recurrent or multiple cancers (40.9% vs. 33.7%; P < .049).[3]
A similar association was seen in an analysis using data from the 2008–2010 Medical Expenditures Panel Survey (MEPS) Household Component to measure loss of employment and productivity in individuals with and without cancer.[1] In this study, survivors with more-aggressive disease processes (i.e., recurrent, multiple, or poor-prognosis cancers) had the highest rates of lost productivity relative to individuals without cancer. Specifically, individuals with cancers associated with short survival were less likely to be employed (66.8% vs. 81.4%; P < .0001) and more likely to face limitations on their ability to participate in activities at home, work, or school (17.5% vs. 8.5%; P < .001) than individuals without cancer. Productivity among survivors of breast, prostate, colorectal, and other single cancers was not as decreased as productivity among those with higher-risk disease.
Sources: 1
Another study used multiple years of the MEPS (2008‒2013) to evaluate the associations between cancer history, chronic conditions, and productivity losses.[5] Adult cancer survivors were significantly more likely to have chronic conditions, including heart disease, diabetes, asthma, and arthritis, than were adults without a cancer history. They were also more likely to have multiple chronic conditions. Cancer survivors who had multiple chronic conditions were more likely to be limited in their ability to work than cancer survivors without these other conditions. Among cancer survivors, those with four or more chronic conditions had annual productivity loss of $9,099 (95% confidence interval [CI], $7,224‒$10,973) compared with those without any additional chronic conditions (in 2013 dollars).
Sources: 5
Receipt of cancer-directed treatment and the presence of other comorbidities were also found to be associated with higher out-of-pocket spending in the Medicare population. In a study using data from the Medicare Current Beneficiary Survey linked to Medicare claims (1997–2007), 2-year mean out-of-pocket spending was higher by $1,526 among patients receiving chemotherapy and by $1,470 among patients receiving radiation therapy compared with patients who did not receive treatment (P < .01).[6]
Sources: 6
These studies suggest that cancer survivors across a broad age range with advanced cancers, recurrent cancers, or cancers that require treatment (likely a marker of more-advanced disease) are more likely to face higher out-of-pocket spending and are at higher risk of financial hardship. Chronic treatment-related spending in combination with inability to regain employment and income resulting from progressive disease and debility may contribute to the association between advanced disease and greater financial burden.
This page is made by Triangle. The reading above is selected source text, not a treatment recommendation, and it is not medical advice.
Source: Financial Toxicity and Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 29, 2024. Captured 2026-09-09.
Several retrospective cohort studies have evaluated the effect of prescription copayment amounts for cancer drugs on patient compliance with therapy.[1,2]
A cross-sectional study using data from the 2011 to 2014 National Health Interview Survey found that individuals aged 18 to 64 years with a recent or previous cancer diagnosis were more likely to report changing their prescription drug use (e.g., not filling prescriptions or skipping doses) for financial reasons than individuals without a history of cancer.[3] Another study examined the association between imatinib copayment and medication adherence among patients with chronic myeloid leukemia, from 2002 to 2011, using MarketScan health plan claims.[1] Over the study period, monthly copayments for imatinib ranged from $0 to $4,792, with a mean and median of $108 and $30, respectively. Patients in the highest quantile of monthly copayments for imatinib (mean, $53) compared with patients in the lowest quantile (mean, $17) had a statistically significant adjusted risk ratio (RR) of 1.70 (95% confidence interval [CI], 1.30–2.22) for discontinuing imatinib during the first 180 days of treatment.[1] Similarly, patients with higher copayments for imatinib (vs. the lower copayment group) had an adjusted RR of 1.42 (95% CI, 1.19–1.69) for nonadherence to their imatinib therapy.[1]
Sources: National Health Interview Survey · 3 · 1 · 1 · 1
Other studies examined the association between copayment amounts for adjuvant endocrine therapy, aromatase inhibitors, and tamoxifen and noncompliance in women with breast cancer.[2,4,5] Studies have been relatively consistent in showing that at the highest levels of copayment, cancer patients become less likely to take cancer-related medications on a daily basis (nonadherence), or they discontinue their medications over the long term (nonpersistence of use). Reduced adherence to cancer medications may be worse when the total out-of-pocket cost of all prescription drugs taken by the patient is considered.[5]
A cross-sectional survey study of adult patients (N = 300) receiving cancer therapy at Duke Cancer Institute found that 16% of patients reported high or overwhelming financial distress, 27% reported medication nonadherence, and 4.67% reported chemotherapy nonadherence.[6] Among patients reporting medication nonadherence, 14% specified skipping medication doses to make the prescription last longer, 11% stated they took less medication than prescribed to make the prescription last longer, and 22% indicated that they did not fill a prescription because of cost.[6] Among the patients reporting chemotherapy nonadherence, 1% skipped chemotherapy doses to make the prescription last longer, 1.67% took less chemotherapy to make the prescription last longer, and 3.33% did not fill a chemotherapy prescription because of cost.
This study also found that an increased likelihood of nonadherence was associated with the following characteristics:
Previous out-of-pocket cost discussion (adjusted odds ratio [OR], 2.58; 95% CI, 1.14–5.85).
Higher financial burden than expected (adjusted OR, 2.90; 95% CI, 1.42–5.89).
High financial distress (adjusted OR, 1.64; 95% CI, 1.38–1.96).
A statistically significant decreased risk of nonadherence was associated with having private insurance (adjusted OR, 0.31; 95% CI, 0.14–0.72).
A cross-sectional cohort study of 10,508 patients who started oral chemotherapy between 2007 and 2009 examined the association between prescription abandonment rates and cost sharing.[7] Abandonment was defined as a paid prescription claim gap of more than 90 days. An adjusted analysis found that claims with cost sharing of $251 to $350 had 2.3 times the likelihood of abandonment (95% CI, 1.59–3.36); $351 to $500 had 3.28 times the likelihood of abandonment (95% CI, 2.20–4.88); and more than $500 had 4.46 times the likelihood of abandonment (95% CI, 3.80–5.22) when compared with cost sharing of $100 or less.[7] Additionally, the study identified a substantially higher proportion of patients who paid more than $500 out of pocket for their first oral chemotherapy claim in the Medicare group compared with the commercially insured group (45.5% vs. 10.7%; P < .001).[7]
Anecdotal reports also suggest that terminally ill cancer patients are foregoing the opportunity to obtain lethal doses of barbiturates in states with death-with-dignity laws because the price of these generic medications has increased to approximately $3,000 for a typical prescription.[8]
Sources: 8
Source: Financial Toxicity and Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 29, 2024. Captured 2026-09-09.
Studies of price transparency initiatives, such as one that required California hospitals to publish their charges, have not found that they significantly influence patient treatment choice or pricing of goods and services by health care providers.[7] Looking at price transparency and provider behavior, one controlled study found that providing clinicians with information about test costs in electronic medical record order-entry forms reduced the number of tests ordered compared with not providing this information.[8] It is not known whether providing price transparency would alter cancer patient or clinician choices for care.
More information is needed regarding how responsive cancer patients, their families, and/or their providers might be to offers of pricing transparency, direct or indirect financial assistance, or further reductions in out-of-pocket payment requirements.
Source: Financial Toxicity and Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 29, 2024. Captured 2026-09-09.
Cancer treatment cost information can be difficult to access. Listed below are links to publicly available websites that contain updated information on costs related to cancer care:
Medicare Part B (office-administered) drug costs.
Medicare benefits (includes information on deductibles and copayments).
Sources: Medicare benefits
Source: Financial Toxicity (Financial Distress) and Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: June 6, 2024. Captured 2026-09-09.
Source: Financial Toxicity (Financial Distress) and Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: June 6, 2024. Captured 2026-09-09.
Financial toxicity describes problems a patient has related to the cost of medical care.
Several studies show that people with cancer and survivors are more likely to have financial toxicity than are people without cancer.
The level of financial toxicity you may have will depend on several factors in your household.
Cancer treatment can affect your ability to work and pay your bills.
Source: Financial Toxicity (Financial Distress) and Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: June 6, 2024. Captured 2026-09-09.
The terms financial toxicity and financial distress are used to describe how out-of-pocket costs can cause financial problems for a patient. Out-of-pocket costs are what you pay for your medical care that is not covered by your health insurance. Out-of-pocket costs include the following:
Sources: financial toxicity · out-of-pocket costs
Copayments: Amount you pay for each health care service, such as a doctor appointment or prescription.
Sources: Copayments · prescription
Deductibles: Amount you pay for your medical care before your health insurance plan begins to pay.
Sources: Deductibles
Coinsurance: Percentage of costs you pay for a service that your health insurance covers after you have paid your deductible; for example, you pay 20% and your insurance pays 80%.
Sources: Coinsurance
These costs can be for hospital stays, outpatient services (procedures and tests that can be done without staying overnight in the hospital), medical appointments, and prescription drugs.
Cancer survivors usually report higher out-of-pocket spending than people who have not had cancer. Some cancer survivors report spending more than 20% of their annual income on medical care.
Sources: survivors
Financial toxicity may also be called financial distress, financial stress, financial hardship, financial burden, economic burden, and economic hardship.
There have been no randomized clinical trials studying financial toxicity in people with cancer. The information in this summary is mainly based on studies that only included survivors and people with certain cancers, so it may not apply to all people with cancer.
Sources: randomized clinical trials
Source: Financial Toxicity (Financial Distress) and Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: June 6, 2024. Captured 2026-09-09.
Cancer is one of the most expensive medical conditions to treat in the United States. People with cancer may receive multiple types of treatments, including radiation therapy and systemic treatment, and may be hospitalized. People with cancer who have health insurance are paying higher premiums than in the past. They are also paying more for copayments, deductibles, and coinsurance.
Sources: radiation therapy · systemic treatment · premiums
Compared to 10 years ago, patients receive more expensive chemotherapy, immunotherapy, and other new types of treatments. Copayments for prescription drugs covered by health insurance may be more for higher priced drugs or brand name drugs (versus generic drugs) and may increase over time. These copayments and coinsurance for drugs may cause financial toxicity even for people with cancer who have health insurance.
Sources: chemotherapy · immunotherapy · generic
Cancer survivors may have financial problems many years after they are diagnosed. This is because they may be paying for ongoing cancer treatment or care for late effects from their treatment.
Sources: diagnosed · late effects
Source: Financial Toxicity (Financial Distress) and Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: June 6, 2024. Captured 2026-09-09.
When you are diagnosed with cancer, the following factors in your household may affect your risk of financial toxicity:
whether you make the most money for your household
how much money other people in your household make
how much debt you had before you were diagnosed with cancer
your assets
Sources: assets
costs related to your cancer
how the cancer and its treatment affect your ability to work
whether you have health and disability insurance and what they cover
Sources: disability insurance
You and your family may have the following problems because of your cancer diagnosis:
less income and assets
debt because of the cost of your cancer care
trouble paying for housing, food, and bills
bankruptcy
Sources: bankruptcy
Source: Financial Toxicity (Financial Distress) and Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: June 6, 2024. Captured 2026-09-09.
Having cancer may make it hard for you to do the physical and mental tasks for your job. You may miss time at work, or not be able to work at all. One study showed that working people who are getting cancer treatment missed about 22 more workdays a year than those who did not have any cancer treatment. Not being able to work may affect your employment-based health insurance (this is when part or all of your premium is paid by your employer).
You may also worry and have stress about paying medical bills related to your cancer. People with cancer have reported worrying about wages lost for sick time or going to medical appointments. You may also have difficulty and stress when trying to understand complex medical bills.
Sources: stress
Source: Financial Toxicity (Financial Distress) and Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: June 6, 2024. Captured 2026-09-09.
Patients with the following types of diseases have a higher risk of financial toxicity:
Sources: financial toxicity
advanced cancer
Sources: advanced cancer
recurrent cancer
Sources: recurrent cancer
cancer that has a poor prognosis
Sources: prognosis
more than one type of cancer
a chronic disease (such as heart disease or diabetes) in addition to cancer
Sources: chronic · heart disease · diabetes
This is partly because their cancer and treatment may keep them from having a job.
Patients who have been treated with chemotherapy and radiation therapy are more likely to have higher out-of-pocket costs and financial toxicity than patients who have not had those treatments.
Sources: chemotherapy · radiation therapy · out-of-pocket costs
Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVB Colon Cancer, Stage IVB Rectal Cancer
ClinicalTrials.gov record